NCT06363734 2024-04-16Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II TrialTianjin Medical University Cancer Institute and HospitalPhase 2 Recruiting32 enrolled